Johns Hopkins researchers are conducting a research study examining the effects of pre-exposure prophylaxis (PrEP) in transgender women using gender-affirming hormones.
Transgender women face a higher risk of contracting HIV compared to the general population. However, the interactions between PrEP (a medication people take to prevent getting HIV) and gender-affirming hormone therapy (GAHT) are not fully understood.
The purpose of this research study is to evaluate the relationship between PrEP and GAHT. Qualified participants may receive up to $3,650 in compensation for their time after completing this 3-month study, which will include in-person visits and daily phone calls. Help advance clinical research and join our paid study today!
Principal Investigator: Mark Marzinke JHM IRB# (IRB00203162)
This study aims to understand the relationship between medications to prevent HIV and gender-affirming hormone therapy.
You may qualify for this study if you meet the following criteria.
Key Criteria:
Transgender woman
18 years or older
HIV negative
Not currently on gender-affirming hormone therapy (GAHT) or willing to temporarily stop GAHT
Willing to attend in-person visits at Johns Hopkins Hospital lasting several hours each, which will include IV catheter placement, blood draws, and colon tissue sampling
Willing to have colon biopsies collected
This study involves:
In-person visits to Johns Hopkins Hospital lasting several hours each, which will include IV catheter placement, blood draws, and colon tissue sampling
Daily phone calls with a member of the research team
Daily doses of PrEP and estrogen
You may earn up to $3,650 for completing this research study. You will also be provided with reimbursement for meals and parking.
There is no cost for you to participate in our research program.
To learn more about the study, please contact 410-955-1288 or email DDUResearch@jhmi.edu.